Format

Send to

Choose Destination
See comment in PubMed Commons below
Oncologist. 2008;13 Suppl 3:4-10. doi: 10.1634/theoncologist.13-S3-4.

Safety update on erythropoiesis-stimulating agents: trials within and outside the accepted indications.

Author information

1
Hospital Clinic, Division of Medical Oncology, IDIBAPS, Institut Clinic Malalties Hemato-Oncològiques (ICMHO), University of Barcelona, 08036 Barcelona, Spain. gascon@clinic.ub.es

Abstract

Certain studies in which erythropoiesis-stimulating agents (ESAs) have been given not with the aim of correcting anemia but to achieve higher target levels of hemoglobin have shown significantly poorer survival among treated patients. However, studies in which ESAs were administered with the aim of reducing the need for RBC transfusions in patients with chemotherapy-associated anemia demonstrate that the use of these agents is not associated with any adverse effect on survival when compared with placebo controls. We can therefore be reassured that using ESAs within the labeled indications will not adversely affect patient outcome.

PMID:
18458118
DOI:
10.1634/theoncologist.13-S3-4
[Indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Support Center